Quality of Life and Stigmatization in Children with Congenital Melanocytic Nevi Before and After Nevus Excision

NCT ID: NCT02280889

Last Updated: 2025-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2031-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Congenital melanocytic nevi (CMN) are a quite common congenital disorder. Over years, surgical excision was proposed to the patients because transformation into a malignant skin tumor (melanoma) was feared. Recent data proof that the risk for malignancy was overestimated. Nowadays still a lot of patients express their wish for surgical removal out of aesthetic reasons and psychological impacts. Many patients and families experience stigmatization because of the nevus. To proof a medical indication for surgical removal the investigators want to evaluate the quality of life and stigmatization before and after nevus surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All children with CMN that will have their nevus removed in our surgical department will be asked to participate. The investigators will send a package of questionnaires to evaluate quality of life and stigmatization before nevus surgery. One year after surgical therapy is finished (sometimes more then one session is necessary), the scar will be clinically evaluated and also another questionnaire package will be sent to evaluate the same parameters again. All parameters are checked for the patients and the families as well. Therefore self and proxy reports of the parents are asked. Moreover, for the patients this is done with interviews in case they are older than 7 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Life Stigmatization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with a congenital melanocytic nevi of at least 2 cm2 that will be removed surgically
* age between 9 months and 16 years

Exclusion Criteria

* mental retardation of the child
* insufficient knowledge of the German language of both parents
* severe comorbidities
* previous therapies done for the CMN (dermabrasion, surgery, laser)
Minimum Eligible Age

9 Months

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Children's Hospital, Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathrin Neuhaus, MD

Role: PRINCIPAL_INVESTIGATOR

University Children's Hospital, Zurich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Children's Hospital Zurich, Division of Pediatric Plastic and reconstructive Surgery

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kathrin Neuhaus, MD

Role: CONTACT

+41442497466

Markus Landolt, Prof

Role: CONTACT

+41442496388

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kathrin Neuhaus, MD

Role: primary

+41442497466

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PB_2019-00139

Identifier Type: OTHER

Identifier Source: secondary_id

2013-0242

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.